China CAR-T Cell

Beijing News (reporter Wang Kara) on the evening of March 2, Fosun Kate Bio announced that KFC889, the second CAR-T cell therapy invested by Fosun Kate, was approved for clinical trial, and applied for clinical trial of recurrent or refractory mantle cell lymphoma after receiving second-line or above treatment in the past. Mantle cell lymphoma is a rare […]

Recently, Mrs. Zhang, the first patient in Hunan Province to receive CAR-T (Relma-cel injection), came to Hunan cancer hospital for PET-CT. The curative effect evaluation reached complete remission, and then only regular review and monitoring were needed. On November 29, 2021, the Hematology Department of lymphoma of Hunan cancer hospital issued the first prescription of Relma-cel in Hunan […]

The FDA has approved ciltacabtagene autoleucel (cilta-cel; Carvykti) for the treatment of adult patients with relapsed and/or refractory multiple myeloma. In November 2021, the FDA had extended the Prescription Drug User Fee Act target date for the biologics license application (BLA) seeking the approval of cilta-cel for use in adult patients with relapsed and/or refractory […]

Abstract providing early first-in-human data on GC502 accepted for presentation at American Association for Cancer Research (AACR) Annual Meeting 2022 SUZHOU, China, and PALO ALTO, Calif., Feb. 22, 2022 /PRNewswire/ — Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today […]

Health Henan News: According to information from the Oncology Department of the First Affiliated Hospital of Zhengzhou University, recently, Ms. Liu (pseudonym), a patient with diffuse large B-cell lymphoma, received CAR-T cell therapy(YESCARTA) in the First Affiliated Hospital of Zhengzhou University, and her symptoms were completely relieved. , was successfully discharged from the hospital, and the treatment Ms. […]

Currently, the cost is high because each patient’s CAR-T cells have to be produced individually. In addition to the preliminary research and development expenses, after the listing in the United States, the price is more than 2 million yuan(Chinese currency). Even if you move to China, the cost will be several hundred thousand, so it is […]

Latest clinical data released on ASH in December 2021, Dr Peggy from Lu Daopei hospital talked about the CAR-T therapy for T-ALL. Totally 14 cases, Complete Remission is 100%. Bravo!

The approval for Abecma is based on data obtained from the Phase II Study BB2121-MM-001 and the Phase I Study CRB-401. Bristol-Myers Squibb has received approval from Japan’s Ministry of Health, Labour and Welfare for its therapy Abecma (idecabtagene vicleucel) to treat relapsed or refractory (R/R) multiple myeloma in adults, according to an announcement. Abecma is […]